Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MaxCyteMXCT -2.23%61 Cash Ratio is 10.46 as of Mar. 2026, which is 9% above its 10-year median of 9.61. GuruFocus rates MXCT with a GF Score™ of 61/100 and a GF Value™ of $2.56 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 841 Medical Devices & Instruments companies, MaxCyte ranks better than 96.2% on this metric.
MaxCyte has a Cash Ratio of 10.46. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for MaxCyte's Cash Ratio or its related term are showing as below:
MXCT'
s Cash Ratio Range Over the Past 10 Years
Min: 1.78 Med: 9.61 Max: 20.35
Current: 10.46
During the past 13 years, MaxCyte's highest Cash Ratio was 20.35. The lowest was 1.78. And the median was 9.61.
MXCT's Cash Ratio is ranked better than 96.2% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs MXCT: 10.46
MaxCyte (NAS:MXCT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
MaxCyte Cash Ratio Related Terms
MaxCyte Cash Ratio Historical Data
* Premium members only.
The historical data trend for MaxCyte's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Cash Ratio distribution charts can be found below:
* The bar in red indicates where MaxCyte's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a Cash Ratio of 10.46 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on MaxCyte and its competitors. This is near median its historical median of 9.61. Over the past decade, MaxCyte's Cash Ratio has ranged from 1.78 to 20.35. According to the industry distribution chart, MaxCyte ranks #32 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 3.8%.
Is MaxCyte's Cash Ratio too high?
MaxCyte's current Cash Ratio of 10.46 is near median its 10-year median of 9.61. Over the past 10 years, this metric has ranged from a low of 1.78 to a high of 20.35. The Medical Devices & Instruments industry median Cash Ratio is 0.97. MaxCyte's value of 10.46 is 978.4% above this industry median. Based on the distribution chart, MaxCyte ranks #32 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MaxCyte has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Cash Ratio compare to RCEL and HYPR?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #32 out of 841 companies for Cash Ratio. This places MaxCyte in the top 4% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.97. MaxCyte's value of 10.46 is 978.4% above this benchmark. Historically, MaxCyte's own Cash Ratio has ranged from 1.78 to 20.35 over the past decade. While the company's 10-year median is 9.61 vs. the industry median of 0.97, MaxCyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Cash Ratio of 10.46 is 978.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Cash Ratio is 10.46, which is near median its own 10-year median of 9.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.56, compared to a current price of $1.10 — trading 57.2% below its estimated fair value. The current Cash Ratio is 10.46, which is near median its 10-year median of 9.61 and 978.4% above the Medical Devices & Instruments industry median of 0.97. MaxCyte's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For MaxCyte (MXCT), the current Cash Ratio is 10.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.10 is trading 57.2% below its estimated GF Value™ of $2.56.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Cash Ratio: 10.46 (near median its 10-year median of 9.61)
GF Value™: $2.56 vs. price of $1.10 (57.2% below fair value)
Industry Position: 978.4% above the Medical Devices & Instruments median (#32 of 841)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
61GF Score
Get the complete analysis for MXCT
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
